Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,500.00 at Royal Bank Of Canada

Eli Lilly and Company (NYSE:LLY) had its target price increased by equities researchers at Royal Bank Of Canada from $1,250.00 to $1,500.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would indicate a potential upside of 22.93% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a report on Monday. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,252.48.

Eli Lilly and Company Trading Down 1.2%

Shares of LLY stock opened at $1,220.23 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock’s 50 day simple moving average is $1,078.08 and its two-hundred day simple moving average is $1,030.27. The company has a market cap of $1.15 trillion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts predict that Eli Lilly and Company will post 35.74 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spire Wealth Management grew its position in Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after buying an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the last quarter. Iams Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $754,000. Finally, Militia Capital Partners LP increased its position in shares of Eli Lilly and Company by 333.3% in the 3rd quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock valued at $1,984,000 after acquiring an additional 2,000 shares during the period. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan lifted its price target on Eli Lilly to $1,400 and reiterated an overweight rating, signaling Wall Street expects further upside from the company’s growth story. Article Title
• Positive Sentiment: Investor enthusiasm remains high around Lilly’s obesity and diabetes drugs, with recent commentary pointing to strong sales momentum and expanding access as key drivers of future revenue growth. Article Title
• Positive Sentiment: Articles highlighting Lilly as a potential stock-split candidate underscore how far the shares have run and reflect continued investor confidence in the company’s blockbuster product lineup. Article Title
• Neutral Sentiment: Several media pieces describe Lilly as a market leader in the GLP-1/obesity boom and suggest the stock may still have room to run if demand stays strong and supply improves. Article Title
• Neutral Sentiment: Broader market coverage noted Lilly “shines” while other biotech and tech names sold off, but that appears to reflect relative strength rather than a company-specific catalyst. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.